Angiomotin Counteracts the Negative Regulatory Effect of Host WWOX on Viral PPxY-Mediated Egress

Jingjing Liang,^a Gordon Ruthel,^a Cari A. Sagum,^b Mark T. Bedford,^b Sachdev S. Sidhu,^c Marius Sudol,^d Chaitanya K. Jaladanki,^e Hao Fan,^{e,f,g} Bruce D. Freedman,^a Ronald N. Harty^a

^aDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

^bDepartment of Epigenetics and Molecular Carcinogenesis, M. D. Anderson Cancer Center, University of Texas, Smithville, Texas, USA

^cDepartment of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada

^dDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

^eBioinformatics Institute, Agency for Science, Technology, and Research, Singapore

^fDepartment of Biological Sciences, National University of Singapore, Singapore

^gCenter for Computational Biology, Duke-NUS Medical School, Singapore

ABSTRACT *Filoviridae* family members Ebola virus (EBOV) and Marburg virus (MARV) and *Arenaviridae* family member Lassa virus (LASV) are emerging pathogens that can cause hemorrhagic fever and high rates of death in humans. A better understanding of the interplay between these viruses and the host will provide information about the biology of these pathogens and may lead to the identification of new targets for therapeutic development. Notably, expression of the filovirus VP40 and LASV-Z matrix proteins alone drives assembly and egress of virus-like particles (VLPs). The conserved PPxY late (L)-domain motifs in the filovirus VP40 and LASV-Z proteins play a key role in the budding process by mediating interactions with select host WW-domain-containing proteins, which then regulate virus egress and spread. To identify the full complement of host WW-domain interactors, we utilized wild-type and mutant PPxY peptides from EBOV and MARV VP40 and LASV-Z proteins to screen an array of glutathione S-transferase-WW-domain fusion proteins. We identified WW-domain-containing oxidoreductase (WWOX) as a novel PPxY-dependent interactor, and we went on to show that full-length WWOX physically interacts with EBOV VP40, MARV VP40, and LASV-Z to negatively regulate egress of VLPs and of a live vesicular stomatitis virus-EBOV recombinant virus (M40). Interestingly, WWOX is a versatile host protein that regulates multiple signaling pathways and cellular processes via modular interactions between its WW-domains and PPxY motifs of select interacting partners, including host angiomotin (AMOT). Notably, we demonstrated recently that expression of endogenous AMOT not only positively regulates egress of VLPs but also promotes egress and spread of live EBOV and MARV. Regarding the mechanism of action, we show that the competitive and modular interplay among WWOX, AMOT, and VP40/Z regulates VLP and M40 virus egress. Thus, WWOX is the newest member of an emerging group of host WW-domain interactors (e.g., BAG3 and YAP/TAZ) that negatively regulate viral egress. These findings further highlight the complex interplay of virus-host PPxY/WW-domain interactions and their potential impact on the biology of both the virus and the host during infection.

IMPORTANCE Filoviruses (EBOV and MARV) and arenavirus (LASV) are zoonotic, emerging pathogens that cause outbreaks of severe hemorrhagic fever in humans. A fundamental understanding of the virus-host interface is critical for understanding the biology of these viruses and for developing future strategies for therapeutic intervention. Here, we identified host WW-domain-containing protein WWOX as a novel interactor with VP40 and Z and showed that WWOX inhibited budding of

Citation Liang J, Ruthel G, Sagum CA, Bedford MT, Sidhu SS, Sudol M, Jaladanki CK, Fan H, Freedman BD, Harty RN. 2021. Angiomotin counteracts the negative regulatory effect of host WWOX on viral PPxY-Mediated egress. *J Virol* 95:e00121-21. <https://doi.org/10.1128/JVI.00121-21>.

Editor Susana López, Instituto de Biotecnología/UNAM

Copyright © 2021 American Society for Microbiology. All Rights Reserved.

Address correspondence to Ronald N. Harty, rharty@vet.upenn.edu.

Received 26 January 2021

Accepted 26 January 2021

Accepted manuscript posted online 3 February 2021

Published 25 March 2021

VP40/Z VLPs and live virus in a PPxY/WW-domain-dependent manner. Our findings are important to the field as they expand the repertoire of host interactors found to regulate PPxY-mediated budding of RNA viruses and further highlight the competitive interplay and modular virus-host interactions that impact both the virus life cycle and the host cell.

KEYWORDS Ebola virus, Marburg virus, Lassa virus, WWOX, angiotensin, VLPs, budding, WW-domain, PPxY motif, virus-host interactions

Hemorrhagic fever viruses (HFVs) are global public health threats that can cause sporadic outbreaks and severe disease in humans (1). Among these emerging pathogens, *Filoviridae* family members Ebola virus (EBOV) and Marburg virus (MARV) and *Arenaviridae* family member Lassa virus (LASV) represent three deadly HFVs (2, 3) that have been the cause of numerous and recent outbreaks of disease (4–6). A better understanding of the molecular aspects of HFV infections and host interactions is critical for the development of new countermeasures to combat these emerging pathogens.

The VP40 matrix proteins of EBOV and MARV and the Z matrix protein of LASV coordinate virion assembly and mediate egress of infectious virus (7–14). Independent expression of VP40 or Z in mammalian cells leads to the formation and egress of virus-like particles (VLPs) via a mechanism that closely mimics the formation and egress of infectious virions. To achieve this, VP40 and Z possess late (L) budding domains that function to recruit or to hijack select host proteins that then facilitate virus-cell separation and virus spread (15–20). For example, the amino acid sequence of PPxY is a conserved L-domain motif in EBOV VP40 (eVP40), MARV VP40 (mVP40), and LASV-Z, and early studies by our group and others demonstrated that the viral PPxY motif mediates interactions with specific WW-domain-containing host proteins (21–23) such as E3 ubiquitin ligases (e.g., Nedd4, Itch, and WWP1) to positively regulate virus egress (20, 24–29). Since L-domains are utilized by a wide range of viruses that have significant public health importance, the identification of common host interactors and regulators will provide important insights into the biology and pathogenesis of these viruses and may reveal new targets for the development of broad-spectrum antiviral strategies.

Recently, we screened an array of approximately 115 mammalian WW-domains displayed as glutathione S-transferase (GST) fusion proteins with either wild-type (WT) or PPxY mutant peptides from VP40 and Z protein in an effort to identify the full complement of host WW-domain interactors that may regulate virus egress and spread. In addition to identifying previously described positive interactors such as Nedd4, we surprisingly identified specific host WW-domain-containing interactors (e.g., BAG3 and YAP/TAZ) that we found to negatively regulate egress of VP40 and Z VLPs (30–33). Here, we describe the identification of host WW-domain-containing oxidoreductase (WWOX) as the newest member of this emerging list of PPxY interactors that negatively regulate viral PPxY-mediated budding. Indeed, we demonstrate that WW-domain 1 (WW1) of WWOX, a multifunctional tumor suppressor, specifically interacts with the PPxY motifs of eVP40, mVP40, and LASV-Z proteins to inhibit VLP egress. Our identification of WWOX as the newest negative regulator of viral PPxY-mediated budding is particularly intriguing since, like YAP/TAZ and BAG3, WWOX plays a key role in regulating physiologically important cellular pathways, such as transcription (Hippo pathway), apoptosis, cytoskeletal dynamics, and tight junction (TJ) formation, via PPxY/WW-domain interactions (34–43). Notably, a robust interacting partner of WWOX, YAP, and BAG3 is angiotensin (AMOT) (38, 45–47), a multi-PPxY-containing protein that functions as a “master regulator” of Hippo pathway (YAP/TAZ) signaling, cytoskeletal dynamics, cell migration/proliferation, and TJ integrity (45, 46, 48–55). Since we demonstrated recently that expression of endogenous AMOT is critical for positively regulating the budding of VLPs, as well as the egress and spread of live EBOV and MARV in cell culture (32, 33), we postulated that the competitive interplay among VP40/Z, AMOT, and

FIG 1 Identification of WWOX as a host interactor with filovirus and arenavirus matrix proteins. (A) Schematic diagrams of eVP40, mVP40, and LASV-Z proteins, showing amino acid numbers and locations of L-domain motifs. (B) Schematic diagram of the WW-domain array. Each lettered square contains 12 WW- and/or SH3-GST fusion proteins in duplicate. A mock (M) GST control is in the center of each square. The biotinylated WT PPxY or PPxY mutant peptides of eVP40, mVP40, and LASV-Z were used to probe the array. (C to E) The fluorescent patterns for box E, indicating positive interactions between the indicated WT PPxY peptide and specific WW-domains. The WT mVP40 (D) and LASV-Z (E) peptides interacted with WW1 of WWOX (yellow ovals). The WT eVP40 (C) peptide did not interact with WW1 of WWOX (dashed yellow oval).

WWOX may contribute mechanistically to the regulation of VLP and virus egress. Indeed, we found that eVP40 and mVP40 proteins were localized away from the site of budding at the plasma membrane (PM) in the presence of WWOX. In addition, we found that AMOT p130, but not PPxY-lacking AMOT p80, could rescue budding of VP40 VLPs and live virus from the inhibitory effect of WWOX. In sum, our findings here identify host WWOX as a novel PPxY interactor with VP40 and Z proteins and suggest that modular mimicry between viral and host PPxY motifs (AMOT) and the competitive nature of their binding to the same WW-domain interactor (WWOX) impacts late stages of the virus life cycle and perhaps cellular processes as well.

RESULTS

Identification of WWOX as a WW-domain interactor with VP40 and Z matrix proteins. The PPxY L-domain motif is conserved in eVP40, mVP40, and LASV-Z matrix proteins (Fig. 1A), where it plays key roles in mediating host interactions and regulating virus egress. We used biotinylated WT or PPxY mutant peptides from not only eVP40 but also mVP40 and LASV-Z to screen an array of mammalian WW-domains arranged

in 14 squares (A to N), each containing a GST-alone control (M) and 12 duplicate samples of GST-WW-domain fusion proteins, to identify novel PPxY interactors (Fig. 1B). We identified a select set of specific WW-domain interactors for each of the WT peptides (Fig. 1C to E); however, no WW-domain interactors were detected for any of the viral PPxY mutant peptides (data not shown). In addition to detecting many previously characterized and expected WW-domain interactors, such as Nedd4, WWP1, and BAG3, we unexpectedly identified for the first time WWOX as a novel interactor with the PPxY motifs of mVP40 (Fig. 1D) and LASV-Z (Fig. 1E) but not with the PPxY motif of eVP40 (Fig. 1C). Interestingly, WWOX is a multifunctional tumor suppressor that plays key roles in regulating physiologically important cellular pathways, such as transcription (Hippo pathway), apoptosis, cytoskeletal dynamics, and TJ formation, via host PPxY/WW-domain interactions (35, 37, 38, 40, 42, 56). These results not only warrant further investigations into a possible role for host WWOX as a viral PPxY interactor and effector of viral egress but also highlight the selectivity, context specificity, and potential competitive interplay of these modular PPxY/WW-domain interactions.

GST pulldown assays confirm VP40/Z-WWOX interactions. WWOX contains two WW-domains, separated by a nuclear localization signal and followed by a short-chain dehydrogenase/reductase (SDR) domain (Fig. 2A). WW1 has the typical domain structure and is the main functional domain known to mediate multiple interactions with host PPxY-containing proteins. In contrast, WW2 has an atypical structure due to the replacement of one of its signature tryptophan (W) residues by a tyrosine (Y) residue, such that WW2 functions as a chaperone to facilitate the binding of PPxY ligands to WW1 (57). Here, we used purified GST fusion proteins of WW1 and WW2 (Fig. 2B) in pulldown assays to determine whether they interact with PPxY motifs present in full-length eVP40, mVP40, and LASV-Z proteins expressed in HEK293T cells (Fig. 2C to E). Briefly, cell lysates from HEK293T cells expressing either WT or PPxY mutant viral proteins were incubated with GST alone, GST-WW1, or GST-WW2, and viral interactors were detected by Western blotting. We found that WT eVP40, mVP40, and LASV-Z proteins interacted with WW1 of WWOX (Fig. 2C to E, lanes 3) but not with WW2 (Fig. 2C to E, lanes 5). The PPxY mutant proteins did not interact with either WW1 or WW2. Interestingly, our results using this approach showed that full-length WT eVP40 interacted with WW1 of WWOX, although an interaction between the eVP40 WT peptide and WW1 of WWOX was not detected in the array screen (Fig. 1).

Coimmunoprecipitation to confirm that full-length VP40/Z and WWOX interact. Here, we used a coimmunoprecipitation approach to determine whether VP40/Z proteins interact with full-length WWOX protein in mammalian cells. HEK293T cells were cotransfected with WWOX alone or WWOX plus WT or PPxY mutant forms of VP40/Z, and cell extracts were immunoprecipitated with nonspecific IgG or antisera to detect VP40/Z proteins (Fig. 3). We observed that WWOX interacted robustly with WT eVP40 (Fig. 3A, lane 6) and WT mVP40 (Fig. 3B, lane 6) but did not interact strongly with either VP40 PPxY mutant (Fig. 3A and B, lanes 5). Since our anti-Z antiserum is most efficient in detecting LASV-Z by Western blotting, we used anti-WWOX antiserum first for immunoprecipitation, followed by anti-Z antiserum (Fig. 3C). Indeed, we detected an interaction between WWOX and WT LASV-Z (Fig. 3C, lane 6) but not the PPxY mutant of Z (Fig. 3C, lane 5).

We next sought to determine whether VP40 and Z interact with endogenous WWOX. Human MCF7 cells were either mock transfected or transfected with WT eVP40, mVP40, and LASV-Z, and cell extracts were immunoprecipitated with either nonspecific IgG as a negative control, the appropriate anti-VP40/Z antiserum followed by Western blotting with anti-WWOX antiserum, or the appropriate anti-VP40/Z antiserum followed by Western blotting with the same anti-VP40/Z antiserum as a positive control (Fig. 4). Endogenous WWOX was detected in precipitates from cells expressing eVP40 (Fig. 4A, lane 3), mVP40 (Fig. 4B, lane 3), and LASV-Z (Fig. 4C, lane 3) but not in mock-transfected cells (Fig. 4, lanes 2) or in IgG controls (Fig. 4A, lane 1). Taken together, these results show that full-length eVP40, mVP40, and LASV-Z interacted with exogenous and endogenous full-length WWOX.

FIG 2 GST pull-down assays of VP40/Z and WWOX. (A) Schematic diagram of the 414-amino-acid WWOX protein, highlighting the locations of WW1 (pink), WW2 (blue), the nuclear localization signal (NLS) (green), and the SDR domain (orange). (B) Purified GST, GST-WWOX-WW1, and GST-WWOX-WW2 fusion proteins in the input (left) and pull-downs (right) detected by Western blotting using anti-GST antibody. (C to E) (Left) Western blots of HEK293T cell extracts, showing expression of the indicated input WT or mutant PPxY proteins (lanes 1 and 2). (Right) Western blots of full-length WT and PPxY mutants of eVP40, mVP40, and LASV-Z pulled down with either GST alone (lanes 1 and 2), GST-WWOX-WW1 (lanes 3 and 4), or GST-WWOX-WW2 (lanes 5 and 6).

WWOX inhibits filovirus and arenavirus VLP egress. Next, we investigated whether expression of WWOX would affect egress of VP40/Z using our well-established VLP budding assay. Briefly, HEK293T cells were transfected with WT or PPxY mutant forms of VP40/Z in the absence or presence of exogenous WWOX, and both cell extracts and VLPs were harvested at 24 h posttransfection. VP40/Z and WWOX proteins

FIG 3 WWOX interacts with VP40/Z in a PPXY-dependent manner. (A) (Right) Extracts from HEK293T cells transfected with the indicated plasmids were immunoprecipitated (IP) with either normal rabbit IgG or anti-eVP40 antiserum, and the precipitated proteins were analyzed by Western blotting (WB) using mouse anti-Myc (WWOX) or anti-eVP40 antiserum (lanes 1 to 6). (Left) Expression controls for eVP40, eVP40-ΔPT/PY, WWOX, and β-actin are shown (lanes 1 to 3). (B) (Right) Extracts from HEK293T cells transfected with the indicated plasmids were immunoprecipitated with either normal mouse IgG or mouse anti-FLAG (mVP40) antiserum, and the precipitated proteins were analyzed by Western blotting using rabbit anti-Myc (WWOX) or mouse anti-FLAG antiserum (lanes 1 to 6). (Left) Expression controls for mVP40, mVP40-P>A, WWOX, and β-actin are shown (lanes 1 to 3). (C) (Right) Extracts from HEK293T cells transfected with the indicated plasmids were immunoprecipitated with either normal mouse IgG or anti-myc (WWOX) antiserum, and the precipitated proteins were analyzed by Western blotting using mouse anti-Myc (WWOX) or rabbit anti-LASV-Z antisera (lanes 1 to 6). (Left) Expression controls for LASV-Z, LASV-Z-ΔPY, WWOX, and β-actin are shown (lanes 1 to 3).

were detected in the appropriate cell extracts by Western blotting, and actin was also detected as a loading control (Fig. 5A to C, cell lysates). Interestingly, we found that expression of WWOX inhibited egress of eVP40, mVP40, and LASV-Z VLPs (Fig. 5A to C, compare lanes 1 and 2 in each panel). As expected, the PPXY mutant VP40/Z proteins

FIG 4 VP40/Z interacts with endogenous WWOX. MCF7 cells were mock transfected or transfected with HA-tagged eVP40 (A), FLAG-tagged mVP40 (B), or HA-tagged LASV-Z (C) as indicated. Extracts were first immunoprecipitated (IP) with either mouse IgG as a negative control, anti-HA, or anti-FLAG antiserum as indicated, and precipitates were then analyzed by Western blotting (WB) using anti-WWOX antiserum (bottom blots, lanes 1 to 3). Precipitates were also analyzed by Western blotting using mouse anti-HA or anti-FLAG antibodies as positive controls (top blots, lanes 1 to 3). Expression (input) controls for endogenous WWOX and β -actin, as well as exogenous eVP40, mVP40, and LASV-Z, are shown (input, lanes 4 and 5).

were themselves defective in VLP budding in the absence and presence of WWOX (Fig. 5A to C, compares lanes 3 and 4 in each panel).

To determine whether the inhibitory effect of WWOX on VLP egress was dose dependent, HEK293T cells were transfected with a constant amount of VP40/Z and increasing amounts of WWOX (Fig. 6). We observed a robust and consistent dose-dependent inhibitory effect of WWOX on the egress of eVP40 (Fig. 6A and B), mVP40 (Fig. 6C and D), and LASV-Z (Fig. 6E and F) VLPs in multiple independent experiments. Indeed, budding of eVP40 and mVP40 VLPs was reduced by approximately 80% when equal amounts of VP40 and WWOX plasmids were cotransfected (Fig. 6B and D). Interestingly, inhibition of LASV-Z VLP budding was as pronounced as 80% in the presence of only one-half of the amount of WWOX plasmid as used for VP40 experiments (Fig. 6E and F). Together, our results indicate that WWOX is a novel, broad-spectrum PPxY interactor that negatively regulates egress of VP40/Z VLPs.

WW1 of WWOX interacts physically and functionally with VP40/Z proteins. We next sought to determine whether WW1 of WWOX specifically was important for mediating physical and functional interactions between WWOX and viral PPxY motifs, since WW1 but not WW2 of WWOX bound to full-length eVP40/mVP40 and LASV-Z in our GST pulldown assays. Toward this end, we constructed a WW1 mutant of WWOX (WWOX-W44AP47A) by changing two key amino acids within the domain to alanine, i.e., W44A and P47A (57). HEK293T cells were cotransfected with Myc-tagged WT WWOX or the W44AP47A mutant plus eVP40 (Fig. 7A), mVP40 (Fig. 7C), or LASV-Z (Fig. 7E). Cell extracts were immunoprecipitated with either nonspecific IgG or anti-Myc antibody, and the VP40 and Z proteins were detected in precipitates by Western blotting using appropriate antisera, as indicated (Fig. 7A, C, and E). eVP40, mVP40, and LASV-Z were detected in the WT WWOX precipitates but not in the W44AP47A mutant

FIG 5 WWOX inhibits budding of VP40/Z VLPs in a PPxY-dependent manner. (A to C) HEK293T cells were transfected with the indicated plasmids, and proteins in cell lysates and VLPs were detected by Western blotting and quantified using NIH ImageJ software.

FIG 6 WWOX inhibits budding of VP40/Z VLPs in a dose-dependent manner. (A, C, and E) HEK293T cells were transfected with constant amounts of eVP40, mVP40, or LASV-Z plasmids plus increasing amounts of WWOX. The indicated proteins were detected in cell lysates and VLPs by Western blotting, and proteins in VLPs were quantified (values in parentheses) using NIH ImageJ software. (B, D, and F) Quantification of the relative budding efficiency of eVP40, mVP40, or LASV-Z VLPs under the indicated conditions from three independent experiments ($n=3$) was performed. The ratio of WWOX plasmid to viral plasmid is shown in parentheses. Statistical significance was analyzed by one-way analysis of variance (ANOVA). ns, not significant; *, $P < 0.05$; ****, $P < 0.0001$.

precipitates (Fig. 7A, C, and E, lanes 3 and 4), confirming that WWOX-VP40/Z interactions are mediated by WW1.

Next, we sought to determine whether the mutation of WW1 would affect the ability of WWOX to inhibit VP40/Z VLP egress. Briefly, HEK293T cells were transfected with VP40/Z alone or in combination with either WT WWOX or the W44AP47A mutant. Cell extracts and VLPs were harvested at 24 h posttransfection. While all proteins were

FIG 8 siRNA knockdown of endogenous WWOX positively regulates VLP egress. (A to C) Huh-7 cells were transfected with either random (control) or WWOX-specific siRNAs plus eVP40 (A), mVP40 (B), or LASV-Z (C) plasmids as indicated. Proteins in cell extracts and VLPs were detected by Western blotting and quantified using NIH ImageJ software (values in parentheses). VLP egress from control cells (lane 1) was set at 100%. (D) Quantification of the relative budding efficiency of eVP40, mVP40, and LASV-Z VLPs in the presence of control (blue bars) or WWOX-specific (pink bars) siRNAs from three independent experiments is shown. Statistical significance was analyzed by Student's *t* test, separately. *, *P* < 0.05.

not only for mediating the WWOX-VP40/Z physical interactions but also for mediating the inhibitory effect on VP40/Z VLP budding.

siRNA knockdown of endogenous WWOX enhances VP40/Z VLP egress. Since overexpression of WWOX had a negative regulatory effect on the egress of VP40/Z VLPs, we reasoned that knockdown of endogenous levels of WWOX might have an opposite positive regulatory effect on VP40/Z VLP egress. To test this, we used a small interfering RNA (siRNA) approach to knock down expression of endogenous WWOX in human Huh-7 liver cells and evaluated its effect on VP40/Z VLP egress. Random or WWOX-specific siRNAs plus eVP40, mVP40, or LASV-Z plasmids were transfected into Huh-7 cells, and cell extracts and VLPs were harvested and analyzed by Western blotting (Fig. 8). As expected, WWOX-specific siRNAs, but not random siRNAs, knocked down expression of endogenous WWOX by >70% (Fig. 8A to C, cell lysate). Importantly, we observed consistent 2.5- to 4-fold increases in VP40/Z VLP levels in the presence of WWOX-specific siRNAs, compared to levels in the presence of random control siRNAs, over three independent experiments (Fig. 8A to D, VLPs). These results

FIG 9 WWOX alters the intracellular localization of eVP40 and mVP40. (A and B) HEK293T cells were transfected with eVP40 (A) or mVP40 (B) alone or with WWOX as indicated. Representative images displaying the intracellular localization patterns of eVP40 (green), mVP40 (green), WWOX (red), and nuclei (blue) are shown. Scale bars = 10 μ m. (C and D) HEK293T cells were transfected with eVP40 (C) or mVP40 (D) alone or with WWOX as indicated. The cytosolic, nuclear, and PM fractions were isolated at 24 h posttransfection, and the indicated proteins were detected by Western blotting.

support our conclusion that the newly identified PPxY interactor WWOX represents the newest member of an emerging list of negative regulators of VP40/Z VLP budding.

WWOX alters the intracellular and membrane localization patterns of VP40. To begin to address the mechanism by which WWOX inhibits VLP egress, we sought to determine whether WWOX affects the intracellular localization patterns of VP40. HEK293T cells were transfected with either eVP40 or mVP40 alone or with WWOX, and the intracellular patterns of expression of VP40 and WWOX were visualized by confocal microscopy. As we observed previously, expression of eVP40 or mVP40 alone resulted in their abundant localization at the PM in the form of membrane projections as a result of VLP formation and subsequent egress (Fig. 9A and B, top rows). However, this typical PM pattern of localization for VP40 was altered in the presence of WWOX, such that VP40 exhibited a more internal and punctate pattern of expression with fewer distinct PM projections (Fig. 9A and B). In addition to a reduced amount of VP40 at the PM in the presence of WWOX, we observed what appeared to be a low level of VP40 in the nucleus along with WWOX (Fig. 9A and B). To further assess the altered distribution pattern for VP40 in the presence of WWOX, we isolated cytosolic, nuclear, and PM fractions from cells expressing either VP40 alone or VP40 plus WWOX, and we quantified the proteins by Western blotting (Fig. 9C and D). β -Actin, lamin A/C, and Na/K-ATPase served as markers for the cytosolic, nuclear, and PM fractions, respectively. Consistent with the confocal imaging observations, we observed that the levels of eVP40 and mVP40 were reduced in the PM fractions in cells coexpressing WWOX, compared to

control cells (Fig. 9C and D, plasma membrane). We did not observe any difference in VP40 expression levels in the cytosolic fractions from WWOX-positive versus WWOX-negative cells (Fig. 9C and D, cytosol); however, we did observe an ~ 2 -fold increase in VP40 levels in the nuclei of cells expressing WWOX, compared to those expressing VP40 alone (Fig. 9C and D, nucleus). This finding does correlate well with some of the confocal images showing that VP40 (particularly mVP40) is prevalent in the nucleus in WWOX-expressing cells (Fig. 9B, bottom row). Taken together, these results suggest that WWOX may inhibit the egress of VP40 VLPs, in part, by relocating VP40 away from the site of budding at the PM, as well as perhaps chaperoning a portion of VP40 into the nucleus.

AMOT counteracts the inhibitory effect of WWOX and rescues budding of VP40 VLPs and live virus. We demonstrated recently that the multi-PPxY-containing protein AMOT p130 positively regulates the budding of eVP40 and mVP40 VLPs, as well as the egress and spread of live EBOV and MARV in cell culture (32, 33). Intriguingly, the PPxY motifs of AMOT p130 interact with WW-domains of negative regulators of VP40 budding (YAP, BAG3, and WWOX) (38, 45–47), as well as with WW-domains of positive regulators of VP40 budding (Nedd4 and Itch) (58). AMOT also functions as a master regulator of several physiologically relevant pathways/processes, including the Hippo pathway, apoptosis, cytoskeletal organization at the PM, and TJ integrity (45, 46, 48–50, 52–55). Thus, a potential role for AMOT as a central and key regulator of PPxY-mediated egress of RNA viruses warrants further investigation.

Toward that end, we sought to determine whether the interplay between PPxY-containing AMOT p130 (positive regulator of VP40 budding) and WW-domain-containing WWOX (negative regulator of VP40 budding) would influence the egress of VP40 VLPs. We first utilized a structure-based docking approach to assess the binding potential of the PPxY motifs from eVP40, mVP40, and AMOT p130 to interact with the WW1 of WWOX (Fig. 10A). Using Schrödinger's peptide docking module, we showed that the P1 pocket of WW1 of WWOX (Fig. 10A to C, white module) formed by T27 and W29 (Fig. 10A to C, pink) interacts with the P1 residue of the PPxY motif (Fig. 10A to C, highlighted proline in the green peptide). The Y side chain of the PPxY motif (Fig. 10A to C, highlighted tyrosine in the green peptide) occupies the Y pocket of WW1, which is a hydrophobic groove consisting of side chains from A20, H22, and T27 (Fig. 10A to C, pink). Importantly, the analysis of the protein-peptide docking scores revealed that PPxY motif 2 of AMOT p130 has the greatest potential (the best docking score, i.e., -97.66) to bind to WW1, followed by the mVP40 PPxY motif (score of -79.20) and then the eVP40 PPxY motif (score of -71.11) (Fig. 10A to C).

To determine whether AMOT could rescue the budding of VP40 VLPs in the presence of WWOX, HEK293T cells were transfected with the indicated combinations of plasmids (Fig. 10D to H), and proteins were detected by Western blotting of both cell extracts and VLPs at 24 h posttransfection. Consistent with previous results, we found that expression of AMOT p130 alone did not negatively affect the egress of eVP40 (Fig. 10D, compare lanes 1 and 2) or mVP40 (Fig. 10F, compare lanes 1 and 2) VLPs; however, expression of WWOX significantly inhibited the egress of both VP40 VLPs (Fig. 10D and F, compare lanes 1 and 3). Interestingly, coexpression of AMOT p130 overcame the inhibitory activity of WWOX and rescued the egress of both eVP40 and mVP40 VLPs back to WT levels (Fig. 10D and F, lanes 4 and 5). The ability of AMOT p130 to rescue VP40 VLP egress was dependent on PPxY motifs, since AMOT p80, which lacks all PPxY motifs (Fig. 10H), did not rescue budding of VP40 VLPs (Fig. 10D and F, lanes 6). These results were reproducible and significant in repeated independent experiments (Fig. 10E and G).

Lastly, we sought to determine whether expression of WWOX would impair PPxY-mediated egress of virus and also whether the interplay among the WWOX, AMOT, and viral PPxY motifs regulates the release of virus. Here, we used our previously described vesicular stomatitis virus (VSV) recombinant virus M40 (VSV-M40), which contains the PTAPPEY L-domain motifs and flanking residues from eVP40 in place of the PPxY L-domain motif and flanking residues of VSV M protein (15). Briefly, HEK293T

FIG 10 AMOT rescues VP40 VLP budding in the presence of WWOX. (A to C) Docking models are shown for the following protein-peptide combinations: WWOX WW1 (white) and eVP40 PPxY peptide (MRRVILPTAPPEYMEAI) (green) (A), WWOX WW1 (white) and mVP40 PPxY peptide (MQYLNPPPYADHGANQL) (green) (B), and WWOX WW1 (white) and AMOT PPxY peptide 2 (QLMRYQHPPPEYGAARPA) (green) (C). The first proline (blue) of the PPxY motif occupies the P1 pocket of WWOX WW1, which is formed by W29 and T27, and the Y side chain (pink) of the PPxY motif occupies the Y pocket, which is composed of T27, A20, and H22. (D to G) HEK293T cells were transfected with the indicated combinations of plasmids. Cell lysates and VLPs were harvested, and proteins were analyzed by Western blotting and quantified using NIH ImageJ software (values in parentheses). Bar graphs of eVP40 (E) and mVP40 (G) (Continued on next page)

FIG 11 WWOX and AMOT regulate the release of infectious recombinant virus VSV-M40. (A) HEK293T cells were first transfected with vector alone, WWOX, or WWOX plus AMOT p130 or p80 for 24 h and then were infected with recombinant virus VSV-M40 at an MOI of 0.1 for 8 h. Supernatants were harvested and virus titers were determined by standard plaque assays on BHK-21 cells. Each bar represents the average of three independent experiments performed in duplicate. Statistical significance was analyzed by one-way ANOVA. ns, not significant; ****, $P < 0.0001$. (B) The indicated proteins from VSV-M40-infected cell extracts were detected by Western blotting.

cells were first transfected with vector alone, WWOX, or WWOX plus AMOT p130 or AMOT p80 and then infected with VSV-M40 at a multiplicity of infection (MOI) of 0.1 for 8 h. Cell extracts and supernatants were harvested for Western blot analysis and virus titration, respectively (Fig. 11). Notably, virus titers were significantly lower in the presence of WWOX, compared to control (Fig. 11A). Similar to our observations with VP40 VLPs, virus titers were rescued back to control levels when AMOT p130, but not AMOT p80, was coexpressed with WWOX (Fig. 11A). Expression of viral and host proteins in all samples was confirmed by Western blotting (Fig. 11B). Taken together, these data demonstrate that the competitive interplay among WWOX, AMOT, and VP40 PPxY motifs regulates not only VLP egress but also egress of recombinant virus VSV-M40.

DISCUSSION

WWOX was originally discovered as a tumor suppressor that exerts proapoptotic and inhibitory functions on a variety of tumors (59), and WWOX has been linked to the micropathology of some oncogenic viruses, such as Epstein-Barr virus and human T-cell lymphotropic virus (60–62). WWOX has an extensive and diverse interactome that includes an array of PPxY-containing proteins such as AMOT, p73, AP-2γ, ErbB-4, ezrin, TMEM207, SMAD3, and VOPP1; therefore, WWOX plays a key role in regulating several physiologically important cellular pathways, such as transcription (Hippo pathway), apoptosis, cellular respiration, cytoskeletal dynamics, and TJ formation, via PPxY/WW-domain interactions (34, 37, 38, 40, 41, 51, 63–67). Here, we report on the identification of host WWOX as a novel WW-domain-containing interactor with the PPxY motifs of eVP40, mVP40, and LASV-Z matrix proteins, leading to negative regulation of VP40/Z VLP egress. Although mainly a cytoplasmic protein, WWOX does interact with several transcription factors and can shuttle in and out of the nucleus (35–40, 64, 67). Interestingly, we found that expression of WWOX correlated with modestly increased levels of VP40 detected in the nucleus. This finding raises the possibility not only that WWOX-mediated shuttling of a portion of VP40 into the nucleus could contribute to its

FIG 10 Legend (Continued)

represent data from three independent experiments. Statistical significance was analyzed by one-way ANOVA. ns, not significant; *, $P < 0.05$; ****, $P < 0.0001$. (H) Schematic diagrams of AMOT p130 and AMOT p80, highlighting the locations of LPTY (pink) and two PPEY (blue) motifs, followed by the coiled coil domain (CC) (yellow) and the PSD-95/Dlg1/ZO-1 domain (PDZ) (green).

negative effect on VP40 VLP egress by reducing the amount of VP40 at the PM but also that competitive PPxY/WW-domain interactions among WWOX, VP40, and cellular transcription factors could affect the biology and pathogenesis of the virus. For example, EBOV infection upregulates transforming growth factor β (TGF- β) signaling, and effectors of TGF- β signaling, such as PPxY-containing SMAD3, are activated, leading to the epithelium-to-mesenchyme-like transition (EMT). Reduced expression of cell adhesion molecules and loss of epithelial cell integrity enhanced EBOV pathogenesis (68). Interestingly, WWOX engages in TGF- β signaling (69, 70) and directly binds to the SMAD3 PPxY motif, sequestering SMAD3 in the cytoplasm and thus inhibiting TGF- β signaling and SMAD3 transcriptional activity (65). Indeed, downregulation of WWOX induces EMT, decreases cell attachment, and increases cell motility (71). It will be of interest to determine whether WWOX-VP40 interactions disrupt WWOX function and induce EMT during live EBOV infection.

WWOX is the newest addition to an emerging list of functionally related, host WW-domain interactors (e.g., BAG3 and YAP) that negatively regulate VP40/Z PPxY-mediated budding (30–33). This growing trend suggests that there may be a complex interplay among a wide array of virus-host PPxY/WW-domain interactions occurring during virus infection, and the potential consequent impact of these virus-host interactions on endogenous host PPxY/WW-domain interactions may impact the biology of both the virus and the host during infection. Similar to our findings for negative regulators of budding, BAG3 and YAP-1, WWOX alters the intracellular localization pattern of VP40. Indeed, we not only observed a decrease in localization of VP40 at the PM but also observed more punctate and disorganized staining of VP40, which remained at the PM in shortened protrusions. Thus, the mechanisms by which BAG3, YAP, and WWOX negatively regulate VP40 VLP egress likely involve, at least in part, disruption of VP40 localization and/or assembly at the site of budding at the PM via direct PPxY/WW-domain interactions and subsequent sequestration.

We recently revealed a key role for endogenous AMOT in positively regulating the egress and spread of PPxY-containing filoviruses (32, 33). AMOT p130 contains multiple PPxY motifs that mediate interactions with WW-domains of YAP, BAG3, and WWOX (negative regulators of budding) and, in doing so, function as master regulators of several physiologically relevant pathways/processes, including transcription (Hippo pathway), actin polymerization, and TJ formation/integrity (45–54). Interestingly, stability and turnover of AMOT p130 itself are tightly regulated by PPxY/WW-domain interactions with Nedd4 E3 ubiquitin ligase family members (positive regulators of budding) (58). Thus, the competitive interplay and modular mimicry between the PPxY motifs of AMOT p130, as well as PPxY-containing family members AMOT-L1 and AMOT-L2 (72, 73), and viral VP40/Z proteins for binding to positive or negative host WW-domain interactors to regulate virus egress and dissemination and to affect host pathways is of keen interest. Here, we demonstrated that expression of AMOT p130 rescued the inhibitory effect of WWOX on both VP40 VLP and live virus egress in a PPxY-dependent manner, whereas AMOT p80, which lacks all PPxY motifs, did not rescue VP40 VLP or virus egress. We speculate that the PPxY motifs of AMOT p130 and VP40 may compete for binding to WWOX in virus-infected cells and that the outcome of this virus-host competition would affect virus budding in either a positive or negative manner. In addition, this virus-host competition would likely have an impact on WWOX function and its interactome. For example, ezrin is a membrane-cytoskeleton linker protein that participates in cell adhesion, migration, and assembly of cellular junctions (74–77), and ezrin interacts with the WW-domain of WWOX via its PPVY motif (63). It will be of interest to determine whether filoviral PPxY motifs could disrupt endogenous WWOX-ezrin interactions, resulting in altered membrane-cytoskeleton remodeling and/or cell junction formation and integrity, which could then influence virus spread and pathogenicity.

In sum, we have identified host WWOX as a WW-domain interactor with the PPxY motifs of eVP40, mVP40, and LASV-Z, which negatively regulate egress of VP40/Z VLPs.

The identification of WWOX as the newest negative regulator of viral PPxY-mediated budding is particularly intriguing due to its broad interactome and its regulatory role in several physiologically important pathways. Additional studies at biosafety level 2 (BSL2) and BSL4 will be needed to further dissect the complex molecular and modular interplay among viral PPxY motifs, host PPxY motifs (e.g., AMOT p130), and host WW-domains from both positive (e.g., Nedd4, WWP1, and Itch) and negative (e.g., WWOX, YAP, and BAG3) regulators of virus egress and to assess the biological relevance of these virus-host interactions during live virus infection. Notably, WWOX and AMOT family gene knockout mice are available and will provide valuable models to test the dynamics of these virus-host interactions *in vivo* and in cells derived from these animals (78–80).

MATERIALS AND METHODS

Cell lines and plasmids. HEK293T, MCF-7, BHK-21, and Huh-7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Corning) supplemented with 10% fetal bovine serum (FBS) (GIBCO) and penicillin (100 U/ml)-streptomycin (100 µg/ml) (Invitrogen), and the cells were grown at 37°C in a humidified 5% CO₂ incubator. The plasmids encoding WT eVP40, eVP40-ΔPT/PY, and hemagglutinin (HA)-tagged WT eVP40 were described previously. FLAG-tagged WT mVP40 and mVP40 with a P-to-A substitution were kindly provided by S. Becker (Institut für Virologie, Marburg, Germany). WT LASV-Z and HA-tagged WT LASV-Z were kindly provided by S. Urata (Nagasaki, Japan), and LASV-Z-ΔPY was described previously (14). VP40 and Z proteins are expressed from the pCAGGS vector. The pCMV-Myc-tagged WWOX plasmid was kindly provided by Rami I. Aqeilan (Jerusalem, Israel). The pCMV-Myc-tagged WW1 mutant WWOX was constructed by mutating W44 and P47 to A (alanine). Plasmids expressing Myc-tagged AMOT p130 and p80 were kindly provided by D. McCollum (University of Massachusetts Medical School, MA).

WW-domain array screens. The proline rich motif “reading” array consists of approximately 115 WW- and SH3-domains from mammalian proteins (and yeast). We prepared biotinylated peptides harboring WT or mutated PPxY motifs from EBOV WT VP40 (MRRVILPT**APPEY**MEAI) (boldface type highlights the key amino acids in the sequences that are mediating protein-protein interactions) or mutant VP40 (MRRVILPT**AAAE**AMEAI), MARV WT VP40 (MQYLN**PPPY**ADHGANQL) or mutant VP40 (MQYLN**AAPA**ADHGANQL), and LASV-Z WT (TAPPEIPPSQN**PPPY**SP) or mutant (TAPPEIPPSQN**AAP**ASP). All of the peptides were fluorescently labeled and used to screen the specially prepared “proline-rich” reading array as described previously (32).

GST pulldown assay. GST alone and GST-tagged WWOX WW1 and WW2 fusion proteins were expressed in BL-21 cells and subsequently purified and conjugated to glutathione (GSH) beads (GE Healthcare). HEK293T cells were transfected with WT eVP40, eVP40-ΔPT/PY, FLAG-tagged WT mVP40, mVP40-P>A, WT LASV-Z, or LASV-Z-ΔPY. At 24 h after transfection, the cell extracts were incubated at 4°C for 6 h with the GSH beads described above, with continuous rotation. The protein complexes were pulled down with beads and subjected to Western blot analysis. The rabbit eVP40 antiserum (IBT Bioservices), mouse anti-FLAG antibody (Fitzgerald), and rabbit LASV-Z antiserum (IBT Bioservices) were used to detect eVP40, mVP40, LASV-Z, and their PPxY mutants, respectively. The mouse anti-GST antibody (Sigma) was used to detect GST or GST-WWOX WW1 and WW2 fusion proteins.

Immunoprecipitation assay. HEK293T cells seeded in 6-well plates were transfected with the indicated plasmid combinations using Lipofectamine reagent (Invitrogen). At 24 h posttransfection, cells were harvested and lysed, and the cell extracts were subjected to Western blot analysis and coimmunoprecipitation. The protein complexes were precipitated by either rabbit or mouse IgG and appropriate antisera as indicated. First, the cell extracts were incubated with antiserum overnight at 4°C with continuous rotation, and then the protein A/G agarose beads (Santa Cruz Biotechnology) were added to the mixtures and incubated for 5 h with continuous rotation. After incubation, beads were collected via centrifugation and washed five times. The input cell extracts and immunoprecipitates were then detected by Western blotting with appropriate antisera as indicated. The antisera used included rabbit anti-eVP40, mouse anti-FLAG (for FLAG-tagged mVP40), rabbit anti-LASV-Z, and mouse anti-Myc (Millipore), rabbit anti-Myc (Sigma), mouse anti-HA (Sigma), rabbit anti-WWOX (Cell Signaling Technology), and mouse anti-WWOX (Santa Cruz Biotechnology).

VLP budding assay and WWOX titration. Filovirus VP40 and arenavirus LASV-Z VLP budding assays in HEK293T cells were described previously (14). The eVP40, mVP40, and LASV-Z proteins in VLPs and cell extracts were detected by SDS-PAGE and Western blotting and quantified using NIH ImageJ software. The anti-eVP40 antiserum was used to detect WT eVP40 and the eVP40-ΔPT/PY mutant, the anti-FLAG monoclonal antibody was used to detect FLAG-tagged mVP40 and mVP40-P>A, and the anti-LASV-Z antiserum was used to detect LASV-Z and LASV-Z-ΔPY. For VLP budding and WWOX titration experiments, HEK293T cells were transfected with 0.1 µg of eVP40 or mVP40 or 0.2 µg of LASV-Z and increasing amounts (0.1, 0.5, and 1.0 µg) of WWOX plasmids. The total amounts of transfected DNA were equivalent in all samples. The cell extracts and VLPs were harvested at 24 h posttransfection and subjected to Western blotting.

siRNA knockdown assay. Huh-7 cells seeded in 6-well plates were transfected with human WWOX-specific or random siRNAs (Dharmacon) at a final concentration of 50 nM per well using Lipofectamine 2000 reagent (Invitrogen). At 24 h after siRNA transfection, cells were transfected again with 1.0 µg of

eVP40, mVP40, or LASV-Z plasmid. VLPs and cell extracts were harvested at 48 h posttransfection, and the indicated proteins in cell extracts and VLPs were detected by Western blotting.

Indirect immunofluorescence assay. HEK293T cells were transfected with the indicated plasmid combinations. At 24 h posttransfection, cells were washed with cold phosphate-buffered saline (PBS), fixed with 4% formaldehyde for 15 min at room temperature, and then permeabilized with 0.2% Triton X-100. After three washes with cold PBS, cells were incubated with rabbit anti-eVP40 or anti-FLAG (mVP40) antiserum and mouse anti-Myc (WVOX) antibody. Cells were stained with Alexa Fluor 488-labeled goat anti-rabbit IgG and Alexa Fluor 594-labeled goat anti-mouse IgG secondary antibodies (Life Technologies). Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) in Prolong anti-fade mountant (Thermo Fisher Scientific). Microscopy was performed using a Leica SP5 fluorescence lifetime imaging microscopy (FLIM) inverted confocal microscope. Serial optical planes of focus were taken, and the collected images were merged into one by using the Leica Application Suite AF software.

Cytosolic, nuclear, and PM protein fractionation. HEK293T cells were transfected with the indicated plasmid combinations, and cells were scraped and washed with cold PBS at 24 h posttransfection. Cells were then collected via low-speed centrifugation. The cytosolic, nuclear, and PM fractions were isolated sequentially using the Minute PM protein isolation kit (Invent) following the manufacturer's instructions. Proteins within the cytosolic, nuclear, and PM fractions were detected via SDS-PAGE and Western blotting. β -Actin, lamin A/C, and Na/K-ATPase were used as cytosolic, nuclear, and PM controls, respectively, and were detected using mouse anti- β -actin (Proteintech), mouse anti-lamin A/C (Cell Signaling Technology), and rabbit anti-Na/K-ATPase (Abcam) monoclonal antibodies. The eVP40, mVP40, and WVOX in each subcellular fraction were detected using the antisera mentioned above.

Protein-peptide docking analysis. (i) Homology modeling. The amino acid sequence of WVOX WW1 was obtained from the UniProt database (81) (positions 16 to 49; GenBank accession number Q9NZC7). A sequence similarity search was carried out using the Protein BLAST tool (82) to find protein templates. ClustalW2 (83) was used to generate the target-template sequence alignment. The homology modeling of the WVOX WW1 was performed by Modeller v9.22, based on the template ubiquitin ligase Nedd4 (PDB code 1I5H) (84), which is the closest template to WVOX WW1, with 64% sequence identity. The discrete optimized protein energy (DOPE) (85) scoring function was then used to score the models and to pick the best-scoring model for peptide docking.

(ii) Protein-peptide docking. The protein-peptide docking analysis was carried out using the Glide module. The modeled WW1 of WVOX was prepared using the Protein Preparation Wizard tool in Schrodinger. The peptides were constructed with Maestro, and multiple conformers were generated using the MacroModel sampling method. The receptor grid for peptide docking purposes was generated with default settings and the centroid of the Y18, A20, H22, E25, T27, and W29 residues defined as the grid center. The Glide SP-PEP protocol was used to dock peptide conformers (86).

AMOT-mediated rescue of VLP budding. HEK293T cells were transfected with 0.2 μ g of eVP40 or mVP40 plus 0.5 μ g of WVOX and increasing amounts (0.25 or 0.5 μ g) of AMOT p130 or 0.5 μ g AMOT p80 plasmids. The total amounts of transfected DNA were equivalent in all samples. VLPs and cell extracts were harvested at 24 h posttransfection and then subjected to SDS-PAGE and Western blotting, and results were quantified using NIH ImageJ software.

Transfection/infection assays. HEK293T cells were first transfected for 24 h with pCAGGS vector alone, WVOX (1.0 μ g), or WVOX (1.0 μ g) plus AMOT p130 (0.5 μ g) or AMOT p80 (0.5 μ g) and subsequently were infected with VSV-M40 at an MOI of 0.1. Supernatants and cell extracts were harvested at 8 h postinfection, separately. Released VSV-M40 virions in supernatants were titrated in duplicate via standard plaque assays on BHK-21 cells. Cellular and viral proteins were detected by Western blotting using appropriate antibodies.

ACKNOWLEDGMENTS

We thank S. Becker, S. Urata, R. I. Aqeilan, D. McCollum, and J. Kissil for kindly providing reagents. We thank members of the Harty laboratory for fruitful discussions and suggestions on this work.

Funding was provided in part by National Institutes of Health grants AI138052, AI139392, and EY031465 to R.N.H. Probing of arrayed WW-domains was made possible via the University of Texas M. D. Anderson Cancer Center Protein Array and Analysis Core CPRIT grant RP180804 to M.T.B. H.F. and C.K.J. were supported by the Biomedical Research Council of the Agency for Science, Technology, and Research (A*STAR). The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.

M.T.B. is a cofounder of EpiCypher. B.D.F. and R.N.H. are cofounders of Intervir, LLC.

REFERENCES

1. Salvato MS. 2017. Hemorrhagic fever viruses: methods and protocols. Springer, New York, NY.
2. Kuhn JH, Adachi T, Adhikari NKJ, Arribas JR, Bah IE, Bausch DG, Bhadelia N, Borchert M, Brantsaeter AB, Brett-Major DM, Burgess TH, Chertow DS, Chute CG, Cieslak TJ, Colebunders R, Crozier I, Davey RT, de Clerck H, Delgado R, Evans L, Fallah M, Fischer WA, Fletcher TE, Fowler RA, Grunewald T, Hall A, Hewlett A, Hoepelman AIM, Houlihan CF, Ippolito G, Jacob ST, Jacobs M, Jakob R, Jacquerioz FA, Kaiser L, Kalil AC, Kamara RF,

- Kapetshi J, Klenk H-D, Kobinger G, Kortepeter MG, Kraft CS, Kratz T, Bosa HSK, Lado M, Lamontagne F, Lane HC, Lobel L, Lutwama J, Lyon GM, III, Massaquoi MBF, Massaquoi TA, Mehta AK, Makuma VM, Murthy S, Musoke TS, Muyembe-Tamfum JJ, Nakyeyune P, Nanclores C, Nanyunja M, Nsio-Mbete J, O'Dempsey T, Paweska JT, Peters CJ, Piot P, Rapp C, Renaud B, Ribner B, Sabeti PC, Schieffelin JS, Slenczka W, Soka MJ, Sprecher A, Strong J, Swanepoel R, Uyeki TM, van Herp M, Vetter P, Wohl DA, Wolf T, Wolz A, Wurie AH, Yoti Z. 2019. New filovirus disease classification and nomenclature. *Nat Rev Microbiol* 17:261–263. <https://doi.org/10.1038/s41579-019-0187-4>.
3. Sweileh WM. 2017. Global research trends of World Health Organization's top eight emerging pathogens. *Global Health* 13:9. <https://doi.org/10.1186/s12992-017-0233-9>.
4. Malvy D, McElroy AK, de Clerck H, Günther S, van Griensven J. 2019. Ebola virus disease. *Lancet* 393:936–948. [https://doi.org/10.1016/S0140-6736\(18\)33132-5](https://doi.org/10.1016/S0140-6736(18)33132-5).
5. Boisen ML, Uyigüe E, Aiyepada J, Siddle KJ, Oestereich L, Nelson DKS, Bush DJ, Rowland MM, Heinrich ML, Eromon P, Kayode AT, Odia I, Adomeh DI, Muebonam EB, Akhilomen P, Okonofua G, Osiemi B, Omoriegbe O, Airende M, Agbukor J, Ekhikhametor S, Aire CO, Duraffour S, Pahlmann M, Bohm W, Barnes KG, Mehta S, Momoh M, Sandi JD, Goba A, Folarin OA, Ogbaini-Emovan E, Asogun DA, Tobin EA, Akpede GO, Okogbenin SA, Okokhere PO, Grant DS, Schieffelin JS, Sabeti PC, Gunther S, Happi CT, Branco LM, Garry RF. 2020. Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. *Sci Rep* 10:8724. <https://doi.org/10.1038/s41598-020-65736-0>.
6. Nyakarahuka L, Shoemaker TR, Balinandi S, Chemos G, Kwasiga B, Mulei S, Kyondo J, Tumusiime A, Kofman A, Masiira B, Whitmer S, Brown S, Cannon D, Chiang CF, Graziano J, Morales-Betoulle M, Patel K, Zufan S, Komakech I, Natseri N, Chepkwuri PM, Lubwama B, Okiria J, Kayiwa J, Nkonwa IH, Eyu P, Nakiire L, Okarikod EC, Cheptoyek L, Wangila BE, Wanje M, Tusiime P, Bulage L, Mwebesa HG, Ario AR, Makumbi I, Nakinsige A, Muruta A, Nanyunja M, Homsy J, Zhu BP, Nelson L, Kaleebu P, Rollin PE, Nichol ST, Klena JD, Lutwama JJ. 2019. Marburg virus disease outbreak in Kween District Uganda, 2017: epidemiological and laboratory findings. *PLoS Negl Trop Dis* 13:e0007257. <https://doi.org/10.1371/journal.pntd.0007257>.
7. Kolesnikova L, Ryabchikova E, Shestopalov A, Becker S. 2007. Basolateral budding of Marburg virus: VP40 retargets viral glycoprotein GP to the basolateral surface. *J Infect Dis* 196(Suppl 2):S232–S236. <https://doi.org/10.1086/520584>.
8. Kolesnikova L, Bugany H, Klenk HD, Becker S. 2002. VP40, the matrix protein of Marburg virus, is associated with membranes of the late endosomal compartment. *J Virol* 76:1825–1838. <https://doi.org/10.1128/jvi.76.4.1825-1838.2002>.
9. Capul AA, de la Torre JC, Buchmeier MJ. 2011. Conserved residues in Lassa fever virus Z protein modulate viral infectivity at the level of the ribonucleoprotein. *J Virol* 85:3172–3178. <https://doi.org/10.1128/JVI.02081-10>.
10. Ziegler CM, Eisenhauer P, Manuvelyan I, Weir ME, Bruce EA, Ballif BA, Botten J. 2018. Host-driven phosphorylation appears to regulate the budding activity of the Lassa virus matrix protein. *Pathogens* 7:97. <https://doi.org/10.3390/pathogens7040097>.
11. Harty RN, Schmitt AP, Bouamr F, Lopez CB, Krummenacher C. 2011. Virus budding/host interactions. *Adv Virol* 2011:963192. <https://doi.org/10.1155/2011/963192>.
12. Harty RN. 2018. Hemorrhagic fever virus budding studies. *Methods Mol Biol* 1604:209–215. https://doi.org/10.1007/978-1-4939-6981-4_15.
13. Harty RN. 2009. No exit: targeting the budding process to inhibit filovirus replication. *Antiviral Res* 81:189–197. <https://doi.org/10.1016/j.antiviral.2008.12.003>.
14. Han Z, Madara JJ, Herbert A, Prugar LI, Ruthel G, Lu J, Liu Y, Liu W, Liu X, Wrobel JE, Reitz AB, Dye JM, Harty RN, Freedman BD. 2015. Calcium regulation of hemorrhagic fever virus budding: mechanistic implications for host-oriented therapeutic intervention. *PLoS Pathog* 11:e1005220. <https://doi.org/10.1371/journal.ppat.1005220>.
15. Irie T, Licata JM, Harty RN. 2005. Functional characterization of Ebola virus L-domains using VSV recombinants. *Virology* 336:291–298. <https://doi.org/10.1016/j.virol.2005.03.027>.
16. Urata S, Noda T, Kawaoka Y, Morikawa S, Yokosawa H, Yasuda J. 2007. Interaction of Tsg101 with Marburg virus VP40 depends on the PPPY motif, but not the PT/SAP motif as in the case of Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP. *J Virol* 81:4895–4899. <https://doi.org/10.1128/JVI.02829-06>.
17. Liu Y, Cocka L, Okumura A, Zhang YA, Sunyer JO, Harty RN. 2010. Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles. *J Virol* 84:2294–2303. <https://doi.org/10.1128/JVI.02034-09>.
18. Lu J, Qu Y, Liu Y, Jambusaria R, Han Z, Ruthel G, Freedman BD, Harty RN. 2013. Host IQGAP1 and Ebola virus VP40 interactions facilitate virus-like particle egress. *J Virol* 87:7777–7780. <https://doi.org/10.1128/JVI.00470-13>.
19. Han Z, Madara JJ, Liu Y, Liu W, Ruthel G, Freedman BD, Harty RN. 2015. ALIX rescues budding of a double PTAP/PPEY L-domain deletion mutant of Ebola VP40: a role for ALIX in Ebola virus egress. *J Infect Dis* 212(Suppl 2):S138–S145. <https://doi.org/10.1093/infdis/jiu838>.
20. Licata JM, Simpson-Holley M, Wright NT, Han Z, Paragas J, Harty RN. 2003. Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. *J Virol* 77:1812–1819. <https://doi.org/10.1128/jvi.77.3.1812-1819.2003>.
21. Salah Z, Alian A, Aqeilan RI. 2012. WW domain-containing proteins: retrospectives and the future. *Front Biosci (Landmark Ed)* 17:331–348. <https://doi.org/10.2741/3930>.
22. Chen HI, Sudol M. 1995. The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. *Proc Natl Acad Sci U S A* 92:7819–7823. <https://doi.org/10.1073/pnas.92.17.7819>.
23. Sudol M, Chen HI, Bougeret C, Einbond A, Bork P. 1995. Characterization of a novel protein-binding module: the WW domain. *FEBS Lett* 369:67–71. [https://doi.org/10.1016/0014-5793\(95\)00550-s](https://doi.org/10.1016/0014-5793(95)00550-s).
24. Okumura A, Pitha PM, Harty RN. 2008. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. *Proc Natl Acad Sci U S A* 105:3974–3979. <https://doi.org/10.1073/pnas.0710629105>.
25. Urata S, Yasuda J. 2010. Regulation of Marburg virus (MARV) budding by Nedd4.1: a different WW domain of Nedd4.1 is critical for binding to MARV and Ebola virus VP40. *J Gen Virol* 91:228–234. <https://doi.org/10.1099/vir.0.015495-0>.
26. Han Z, Lu J, Liu Y, Davis B, Lee MS, Olson MA, Ruthel G, Freedman BD, Schnell MJ, Wrobel JE, Reitz AB, Harty RN. 2014. Small-molecule probes targeting the viral PPXY-host Nedd4 interface block egress of a broad range of RNA viruses. *J Virol* 88:7294–7306. <https://doi.org/10.1128/JVI.00591-14>.
27. Han Z, Sagum CA, Bedford MT, Sidhu SS, Sudol M, Harty RN. 2016. ITCH E3 ubiquitin ligase interacts with Ebola virus VP40 to regulate budding. *J Virol* 90:9163–9171. <https://doi.org/10.1128/JVI.01078-16>.
28. Han Z, Sagum CA, Takizawa F, Ruthel G, Berry CT, Kong J, Sunyer JO, Freedman BD, Bedford MT, Sidhu SS, Sudol M, Harty RN. 2017. Ubiquitin ligase WWP1 interacts with Ebola virus VP40 to regulate egress. *J Virol* 91:e00812-17. <https://doi.org/10.1128/JVI.00812-17>.
29. Baillet N, Krieger S, Carnec X, Mateo M, Journeaux A, Merabet O, Caro V, Tangy F, Vidalain PO, Baize S. 2019. E3 ligase ITCH interacts with the Z matrix protein of Lassa and Mopeia viruses and is required for the release of infectious particles. *Viruses* 12:49. <https://doi.org/10.3390/v12010049>.
30. Liang J, Sagum CA, Bedford MT, Sidhu SS, Sudol M, Han Z, Harty RN. 2017. Chaperone-mediated autophagy protein BAG3 negatively regulates Ebola and Marburg VP40-mediated egress. *PLoS Pathog* 13:e1006132. <https://doi.org/10.1371/journal.ppat.1006132>.
31. Han Z, Schwoerer MP, Hicks P, Liang J, Ruthel G, Berry CT, Freedman BD, Sagum CA, Bedford MT, Sidhu SS, Sudol M, Harty RN. 2018. Host protein BAG3 is a negative regulator of Lassa VLP egress. *Diseases* 6:64. <https://doi.org/10.3390/diseases6030064>.
32. Han Z, Dash S, Sagum CA, Ruthel G, Jaladanki CK, Berry CT, Schwoerer MP, Harty NM, Freedman BD, Bedford MT, Fan H, Sidhu SS, Sudol M, Shtanko O, Harty RN. 2020. Modular mimicry and engagement of the Hippo pathway by Marburg virus VP40: implications for filovirus biology and budding. *PLoS Pathog* 16:e1008231. <https://doi.org/10.1371/journal.ppat.1008231>.
33. Han Z, Ruthel G, Dash S, Berry CT, Freedman BD, Harty RN, Shtanko O. 2020. Angiomotin regulates budding and spread of Ebola virus. *J Biol Chem* 295:8596–8601. <https://doi.org/10.1074/jbc.AC120.013171>.
34. Aqeilan RI, Donati V, Gaudio E, Nicoloso MS, Sundvall M, Korhonen A, Lundin J, Isola J, Sudol M, Joensuu H, Croce CM, Elenius K. 2007. Association of WWOX with ErbB4 in breast cancer. *Cancer Res* 67:9330–9336. <https://doi.org/10.1158/0008-5472.CAN-07-2147>.

35. Chang NS, Hsu LJ, Lin YS, Lai FJ, Sheu HM. 2007. WW domain-containing oxidoreductase: a candidate tumor suppressor. *Trends Mol Med* 13:12–22. <https://doi.org/10.1016/j.molmed.2006.11.006>.
36. Bouteille N, Driouch K, Hage PE, Sin S, Formstecher E, Camonis J, Lidereau R, Lallemand F. 2009. Inhibition of the Wnt/ β -catenin pathway by the WWOX tumor suppressor protein. *Oncogene* 28:2569–2580. <https://doi.org/10.1038/onc.2009.120>.
37. Del Mare S, Salah Z, Aqeilan RI. 2009. WWOX: its genomics, partners, and functions. *J Cell Biochem* 108:737–745. <https://doi.org/10.1002/jcb.22298>.
38. Abu-Odeh M, Bar-Mag T, Huang H, Kim T, Salah Z, Abdeen SK, Sudol M, Reichmann D, Sidhu S, Kim PM, Aqeilan RI. 2014. Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks. *J Biol Chem* 289:8865–8880. <https://doi.org/10.1074/jbc.M113.506790>.
39. Wang M, Li Y, Wu M, Wang W, Gong B, Wang Y. 2014. WWOX suppresses cell growth and induces cell apoptosis via inhibition of P38 nuclear translocation in cholangiocarcinoma. *Cell Physiol Biochem* 34:1711–1722. <https://doi.org/10.1159/000366372>.
40. Lo JY, Chou YT, Lai FJ, Hsu LJ. 2015. Regulation of cell signaling and apoptosis by tumor suppressor WWOX. *Exp Biol Med* (Maywood) 240:383–391. <https://doi.org/10.1177/1535370214566747>.
41. Abu-Remaih M, Joy-Dodson E, Schueler-Furman O, Aqeilan RI. 2015. Pleiotropic functions of tumor suppressor WWOX in normal and cancer cells. *J Biol Chem* 290:30728–30735. <https://doi.org/10.1074/jbc.R115.676346>.
42. Chang NS, Lin R, Sze CI, Aqeilan RI. 2019. Editorial: WW domain proteins in signaling, cancer growth, neural diseases, and metabolic disorders. *Front Oncol* 9:719. <https://doi.org/10.3389/fonc.2019.00719>.
43. Chen YA, Lu CY, Cheng TY, Pan SH, Chen HF, Chang NS. 2019. WW domain-containing proteins YAP and TAZ in the Hippo pathway as key regulators in stemness maintenance, tissue homeostasis, and tumorigenesis. *Front Oncol* 9:60. <https://doi.org/10.3389/fonc.2019.00060>.
44. Reference deleted.
45. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, Guan KL. 2011. Angiominin is a novel Hippo pathway component that inhibits YAP oncoprotein. *Genes Dev* 25:51–63. <https://doi.org/10.1101/gad.200011>.
46. Yi C, Shen Z, Stemmer-Rachamimov A, Dawany N, Troutman S, Showe LC, Liu Q, Shimono A, Sudol M, Holmgren L, Stanger BZ, Kissil JL. 2013. The p130 isoform of angiominin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. *Sci Signal* 6:ra77. <https://doi.org/10.1126/scisignal.2004060>.
47. Klimek C, Kathage B, Wördehoff J, Höfheld J. 2017. BAG3-mediated proteostasis at a glance. *J Cell Sci* 130:2781–2788. <https://doi.org/10.1242/jcs.203679>.
48. Paramasivam M, Sarkeshik A, Yates JR, III, Fernandes MJ, McCollum D. 2011. Angiominin family proteins are novel activators of the LATS2 kinase tumor suppressor. *Mol Biol Cell* 22:3725–3733. <https://doi.org/10.1091/mbc.E11-04-0300>.
49. Dai X, She P, Chi F, Feng Y, Liu H, Jin D, Zhao Y, Guo X, Jiang D, Guan KL, Zhong TP, Zhao B. 2013. Phosphorylation of angiominin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. *J Biol Chem* 288:34041–34051. <https://doi.org/10.1074/jbc.M113.518019>.
50. Mana-Capelli S, Paramasivam M, Dutta S, McCollum D. 2014. Angiominins link F-actin architecture to Hippo pathway signaling. *Mol Biol Cell* 25:1676–1685. <https://doi.org/10.1091/mbc.E13-11-0701>.
51. Saigo C, Kito Y, Takeuchi T. 2018. Cancerous protein network that inhibits the tumor suppressor function of WW domain-containing oxidoreductase (WWOX) by aberrantly expressed molecules. *Front Oncol* 8:350. <https://doi.org/10.3389/fonc.2018.00350>.
52. Wells CD, Fawcett JP, Traweger A, Yamanaka Y, Goudreau M, Elder K, Kulkarni S, Gish G, Virag C, Lim C, Colwill K, Starostine A, Metalnikov P, Pawson T. 2006. A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells. *Cell* 125:535–548. <https://doi.org/10.1016/j.cell.2006.02.045>.
53. Moleirinho S, Hoxha S, Mandati V, Curtale G, Troutman S, Ehmer U, Kissil JL. 2017. Regulation of localization and function of the transcriptional co-activator YAP by angiominin. *Elife* 6:e23966. <https://doi.org/10.7554/elifesciences.23966>.
54. Brunner P, Hastar N, Kaehler C, Burdzinski W, Jatzlau J, Knaus P. 2020. AMOT130 drives BMP-SMAD signaling at the apical membrane in polarized cells. *Mol Biol Cell* 31:118–130. <https://doi.org/10.1091/mbc.E19-03-0179>.
55. Bratt A, Birot O, Sinha I, Veitonmäki N, Aase K, Ernkqvist M, Holmgren L. 2005. Angiominin regulates endothelial cell-cell junctions and cell motility. *J Biol Chem* 280:34859–34869. <https://doi.org/10.1074/jbc.M503915200>.
56. Aqeilan RI, Croce CM. 2007. WWOX in biological control and tumorigenesis. *J Cell Physiol* 212:307–310. <https://doi.org/10.1002/jcp.21099>.
57. Farooq A. 2015. Structural insights into the functional versatility of WW domain-containing oxidoreductase tumor suppressor. *Exp Biol Med* (Maywood) 240:361–374. <https://doi.org/10.1177/1535370214561586>.
58. Wang C, An J, Zhang P, Xu C, Gao K, Wu D, Wang D, Yu H, Liu JO, Yu L. 2012. The Nedda4-like ubiquitin E3 ligases target angiominin/p130 to ubiquitin-dependent degradation. *Biochem J* 444:279–289. <https://doi.org/10.1042/BJ20111983>.
59. Bednarek AK, Keck-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K, Brenner AJ, Aldaz CM. 2001. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. *Cancer Res* 61:8068–8073.
60. Lan YY, Wu SY, Lai HC, Chang NS, Chang FH, Tsai MH, Su JJ, Chang Y. 2013. WW domain-containing oxidoreductase is involved in upregulation of matrix metalloproteinase 9 by Epstein-Barr virus latent membrane protein 2A. *Biochem Biophys Res Commun* 436:672–676. <https://doi.org/10.1016/j.bbrc.2013.06.014>.
61. Fu J, Qu Z, Yan P, Ishikawa C, Aqeilan RI, Rabson AB, Xiao G. 2011. The tumor suppressor gene WWOX links the canonical and noncanonical NF- κ B pathways in HTLV-I Tax-mediated tumorigenesis. *Blood* 117:1652–1661. <https://doi.org/10.1182/blood-2010-08-303073>.
62. Chang Y, Lan YY, Hsiao JR, Chang NS. 2015. Strategies of oncogenic microbes to deal with WW domain-containing oxidoreductase. *Exp Biol Med* (Maywood) 240:329–337. <https://doi.org/10.1177/1535370214561957>.
63. Jin C, Ge L, Ding X, Chen Y, Zhu H, Ward T, Wu F, Cao X, Wang Q, Yao X. 2006. PKA-mediated protein phosphorylation regulates ezrin-WWOX interaction. *Biochem Biophys Res Commun* 341:784–791. <https://doi.org/10.1016/j.bbrc.2006.01.023>.
64. Salah Z, Aqeilan R, Huebner K. 2010. WWOX gene and gene product: tumor suppression through specific protein interactions. *Future Oncol* 6:249–259. <https://doi.org/10.2217/fon.09.152>.
65. Ferguson BW, Gao X, Zelazowski MJ, Lee J, Jeter CR, Abba MC, Aldaz CM. 2013. The cancer gene WWOX behaves as an inhibitor of SMAD3 transcriptional activity via direct binding. *BMC Cancer* 13:593. <https://doi.org/10.1186/1471-2407-13-593>.
66. Hussain T, Lee J, Abba MC, Chen J, Aldaz CM. 2018. Delineating WWOX protein interactome by tandem affinity purification-mass spectrometry: identification of top interactors and key metabolic pathways involved. *Front Oncol* 8:591. <https://doi.org/10.3389/fonc.2018.00591>.
67. Bonin F, Taouis K, Azorin P, Petitot A, Tariq Z, Nola S, Bouteille N, Tury S, Vacher S, Bieche I, Rais KA, Pierron G, Fuhrmann L, Vincent-Salomon A, Formstecher E, Camonis J, Lidereau R, Lallemand F, Driouch K. 2018. VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX. *BMC Biol* 16:109. <https://doi.org/10.1186/s12915-018-0576-6>.
68. Kindrachuk J, Wahl-Jensen V, Safronetz D, Trost B, Hoenen T, Arsenault R, Feldmann F, Traynor D, Postnikova E, Kuslik A, Napper S, Blaney JE, Feldmann H, Jahrling PB. 2014. Ebola virus modulates transforming growth factor β signaling and cellular markers of mesenchyme-like transition in hepatocytes. *J Virol* 88:9877–9892. <https://doi.org/10.1128/JVI.01410-14>.
69. Hsu LJ, Schultz L, Hong Q, Van Moer K, Heath J, Li MY, Lai FJ, Lin SR, Lee MH, Lo CP, Lin YS, Chen ST, Chang NS. 2009. Transforming growth factor β 1 signaling via interaction with cell surface Hyal-2 and recruitment of WWOX/WOX1. *J Biol Chem* 284:16049–16059. <https://doi.org/10.1074/jbc.M806688200>.
70. Bendinelli P, Maroni P, Matteucci E, Desiderio MA. 2015. HGF and TGF β 1 differently influenced Wwox regulatory function on Twist program for mesenchymal-epithelial transition in bone metastatic versus parental breast carcinoma cells. *Mol Cancer* 14:112. <https://doi.org/10.1186/s12943-015-0389-y>.
71. Li J, Liu J, Li P, Zhou C, Liu P. 2018. The downregulation of WWOX induces epithelial-mesenchymal transition and enhances stemness and chemoresistance in breast cancer. *Exp Biol Med* (Maywood) 243:1066–1073. <https://doi.org/10.1177/1535370218806455>.
72. Bratt A, Wilson WJ, Troyanovsky B, Aase K, Kessler R, Van Meir EG, Holmgren L, Meir EG. 2002. Angiominin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. *Gene* 298:69–77. [https://doi.org/10.1016/S0378-1119\(02\)00288-9](https://doi.org/10.1016/S0378-1119(02)00288-9).
73. Moleirinho S, Guerrant W, Kissil JL. 2014. The angiominins: from discovery to function. *FEBS Lett* 588:2693–2703. <https://doi.org/10.1016/j.febslet.2014.02.006>.

74. Simonovic I, Arpin M, Koutsouris A, Falk-Krzesinski HJ, Hecht G. 2001. Enteropathogenic *Escherichia coli* activates ezrin, which participates in disruption of tight junction barrier function. *Infect Immun* 69:5679–5688. <https://doi.org/10.1128/iai.69.9.5679-5688.2001>.
75. Pujuguet P, Del Maestro L, Gautreau A, Louvard D, Arpin M. 2003. Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. *Mol Biol Cell* 14:2181–2191. <https://doi.org/10.1091/mbc.e02-07-0410>.
76. Pidoux G, Gerbaud P, Dompierre J, Lygren B, Solstad T, Evain-Brion D, Tasken K. 2014. A PKA-ezrin-Cx43 signaling complex controls gap junction communication and thereby trophoblast cell fusion. *J Cell Sci* 127:4172–4185. <https://doi.org/10.1242/jcs.149609>.
77. Dukic AR, Haugen LH, Pidoux G, Leithe E, Bakke O, Tasken K. 2017. A protein kinase A-ezrin complex regulates connexin 43 gap junction communication in liver epithelial cells. *Cell Signal* 32:1–11. <https://doi.org/10.1016/j.cellsig.2017.01.008>.
78. Ludes-Meyers JH, Kil H, Parker-Thornburg J, Kusewitt DF, Bedford MT, Aldaz CM. 2009. Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene. *PLoS One* 4:e7775. <https://doi.org/10.1371/journal.pone.0007775>.
79. Aase K, Ernkvist M, Ebarasi L, Jakobsson L, Majumdar A, Yi C, Birot O, Ming Y, Kvanta A, Edholm D, Aspenstrom P, Kissil J, Claesson-Welsh L, Shiono A, Holmgren L. 2007. Angiomin regulates endothelial cell migration during embryonic angiogenesis. *Genes Dev* 21:2055–2068. <https://doi.org/10.1101/gad.432007>.
80. Zheng YJ, Vertuani S, Nystrom S, Audebert S, Meijer I, Tegnebratt T, Borg JP, Uhlen P, Majumdar A, Holmgren L. 2009. Angiomin-like protein 1 controls endothelial polarity and junction stability during sprouting angiogenesis. *Circ Res* 105:260–U148. <https://doi.org/10.1161/CIRCRESAHA.109.195156>.
81. UniProt Consortium. 2019. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res* 47:D506–D515. <https://doi.org/10.1093/nar/gky1049>.
82. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. 2009. BLAST+: architecture and applications. *BMC Bioinformatics* 10:421. <https://doi.org/10.1186/1471-2105-10-421>.
83. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. 2007. Clustal W and Clustal X version 2.0. *Bioinformatics* 23:2947–2948. <https://doi.org/10.1093/bioinformatics/btm404>.
84. Kanelis V, Rotin D, Forman-Kay JD. 2001. Solution structure of a Nedd4 WW domain-ENaC peptide complex. *Nat Struct Biol* 8:407–412. <https://doi.org/10.1038/87562>.
85. Shen MY, Sali A. 2006. Statistical potential for assessment and prediction of protein structures. *Protein Sci* 15:2507–2524. <https://doi.org/10.1110/ps.062416606>.
86. Tubert-Brohman I, Sherman W, Repasky M, Beuming T. 2013. Improved docking of polypeptides with Glide. *J Chem Inf Model* 53:1689–1699. <https://doi.org/10.1021/ci400128m>.